TP53 mutations affect ferroptosis-related metabolism and are detrimental to the survival of cancer patients (Jiang et al., 2015), and we observed the presence of TP53 somatic mutations in 63.5% of patients in the high-risk group. Here, TP53 is linked to cancer.